Key Highlights
- 33.4 million is the USD total Revenue Karyopharm Therapeutics Inc. (NASDAQ:KPTI) reported for the second quarter of 2026, including USD 30.8 million of XPOVIO net product revenue, with a net loss of USD 67.0 million.
- 2.32 is the USD net loss per share for the second quarter of 2026, compared with 4.32 a year earlier, as the six month loss reached USD 89.4 million or USD 3.51 per share.
- 110 million is the maximum USD debtor-in-possession financing tied to the November 2, 2026 Chapter 11 filing, which includes up to USD 55 million of new money and a planned Ayrmid merger.
- 130 million to USD 150 million is the 2026 total revenue guidance range reaffirmed in August 2026, set before the Chapter 11 filing, alongside XPOVIO guidance of USD 115 million to USD 130 million.
What Investors Expect From Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on November 16, 2026
Karyopharm Therapeutics Inc. is scheduled to report third quarter 2026 results on November 16, 2026, according to published market data. The company, which sells XPOVIO for multiple myeloma, generated total revenue of USD 146.1 million in 2025. The report arrives two weeks after the company filed voluntary Chapter 11 petitions on November 2, 2026 in the U.S. Bankruptcy Court for the Southern District of Texas. For comparison, the second quarter produced revenue of USD 33.4 million versus USD 37.9 million a year earlier, and a net loss of USD 67.0 million versus USD 37.3 million.
The Rationale: Last Reported Quarter and Management Outlook for Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
In the second quarter, reported on August 13, 2026, XPOVIO net product revenue rose to USD 30.8 million from USD 29.7 million, while license and other revenue fell to USD 2.7 million from USD 8.2 million. Other expense net of USD 32.1 million contributed to the USD 67.0 million net loss. Management reaffirmed 2026 guidance for total revenue of USD 130 million to USD 150 million and combined research and administrative expenses of USD 230 million to USD 245 million, excluding one-time costs. The pivotal development is selinexor plus ruxolitinib in myelofibrosis, with a supplemental application planned for August 2026 under accelerated approval.
Valuation, Liquidity and Risks for Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Cash and investments were USD 65.4 million on June 30, 2026, against a convertible note balance of USD 25.9 million due 2028, USD 98.7 million due 2029, a USD 125.4 million term Loan and a USD 72.3 million deferred Royalty obligation. The Quarterly Report disclosed substantial going-concern doubt, and a USD 15.8 million term loan installment due September 10, 2026 was missed. The restructuring support agreement provides for a Merger with Ayrmid Ltd. Bids are due December 16, 2026. The company expects common stockholders to receive no distribution and to be Delisted from the Nasdaq Global Select Market. Published market data cited a Market Value of USD 2.54 million at a USD 0.1120 close, well under USD 100 million, which carries heightened small-cap risk including Volatility and thin liquidity.
Where Things Stand
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) reports on November 16, 2026 as a company in court-supervised restructuring. Second quarter revenue of USD 33.4 million and a net loss of USD 67.0 million set the baseline, while the USD 130 million to USD 150 million revenue guidance predates the November 2, 2026 filing and may be revised. The Ayrmid merger, USD 55 million of new-money financing, and a December 16, 2026 bid deadline define the timetable. Investors will watch XPOVIO sales, cash use, and the myelofibrosis filing, given the company has said common stockholders are not expected to receive value.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...